RESUMO
Human leukocyte antigen (HLA) types were obtained from 79 Iranian patients with multiple sclerosis and compared with 100 controls. The prevalence of HLA-A24 (30.3% versus 18.0%), HLA-DR2 (43.0% versus 28. 0%) and HLA-DR15 (36.7% versus 23.0%) were significantly increased in multiple sclerosis patients compared with controls. However age at onset, and disease status (relapsing - remitting or primary progressive) did not show an association with any particular HLA type. Multiple Sclerosis (2000) 6 317 - 319
Assuntos
Antígenos HLA-A/análise , Antígenos HLA-A/imunologia , Antígenos HLA-DR/análise , Antígenos HLA-DR/imunologia , Esclerose Múltipla Recidivante-Remitente/imunologia , Adolescente , Adulto , Idade de Início , Linfócitos B/imunologia , Feminino , Predisposição Genética para Doença , Antígeno HLA-A24 , Subtipos Sorológicos de HLA-DR , Antígeno HLA-DR2/análise , Antígeno HLA-DR2/imunologia , Humanos , Irã (Geográfico)/epidemiologia , Masculino , Pessoa de Meia-Idade , Esclerose Múltipla Recidivante-Remitente/epidemiologia , Esclerose Múltipla Recidivante-Remitente/genéticaRESUMO
In an attempt to prevent exacerbations of multiple sclerosis, immunoglobulin therapy was combined with azathioprine (AZA). Intravenous immunoglobulin (i.v.IG) 2 g/kg was given in divided doses over 3 consecutive days followed by monthly booster doses (0.2 g/kg) for 3 years to 38 patients with relapsing-remitting multiple sclerosis (MS). In the 34 patients who completed the trial, the relapse rate decreased (from 1.7 relapses per year to 0 during the 3-year trial period). The Kurtzke Expanded Disability Status Scale decreased from 3.4 +/- 0.72 to 3.0 +/- 0.70. The results suggest that combined i.v.IG and AZA suppress the ongoing pathologic process in relapsing-remitting MS.
